Pu Paul Liu

Pu Paul Liu

Auto-generated profile, based on publicly available information

Pu Paul Liu

National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2017 in Blood
Verified
Journal Article
Open access
PDF file
RSRaman Sood
Raman Sood
YKYasuhiko Kamikubo
Yasuhiko Kamikubo
PLPaul Liu
Paul Liu
RUNX1 is a member of the core-binding factor family of transcription factors and is indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is one of the most frequently mutated genes in a variety of hematological malignancies. Germ line mutations in RUNX1 cause familial platelet disorder with associated myeloid malignancies. Somatic mutations and chromosomal rearrangements involving RUNX1 are frequently observed in myelodysplastic syndrome and leukemias of myeloid and lymphoid lineages, that is, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia. More recent studies suggest that the wild-type RUNX1 is required for growth and survival of certain types of leukemia cells. The purpose of this review is to discuss the current status of our understanding about the role of RUNX1 in hematological malignancies.

1 March 2012 in Cell Stem Cell
Verified
Journal Article
Closed access
LCLinzhao Cheng
Linzhao Cheng
NHNancy F. Hansen
Nancy F. Hansen
LZLing Zhao
Ling Zhao
YDYutao Du
Yutao Du
CZChunlin Zou
Chunlin Zou
PLP. Paul Liu
P. Paul Liu

16 April 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SLSusan E. Lyons
Susan E. Lyons
NLNathan D. Lawson
Nathan D. Lawson
LLLin Lei
Lin Lei
PBPaul E. Bennett
Paul E. Bennett
BWBrant M. Weinstein
Brant M. Weinstein
PLP. Paul Liu
P. Paul Liu
Vlad tepes ( vlt m651 ) is one of only five “bloodless” zebrafish mutants isolated through large-scale chemical mutagenesis screening. It is characterized by a severe reduction in blood cell progenitors and few or no blood cells at the onset of circulation. We now report characterization of the mutant phenotype and the identification of the gene mutated in vlt m651 . Embryos homozygous for the vlt m651 mutation had normal expression of hematopoietic stem cell markers through 24 h postfertilization, as well as normal expression of myeloid and lymphoid markers. Analysis of erythroid development revealed variable expression of erythroid markers. Through positional and candidate gene cloning approaches we identified a nonsense mutation in the gata1 gene, 1015C → T (Arg-339 → Stop), in vlt m651 . The nonsense mutation was located C-terminal to the two zinc fingers and resulted in a truncated protein that was unable to bind DNA or mediate GATA-specific transactivation. A BAC clone containing the zebrafish gata1 gene was able to rescue the bloodless phenotype in vlt m651 . These results show that the vlt m651 mutation is a previously uncharacterized gata1 allele in the zebrafish. The vlt m651 mutation sheds new light on Gata1 structure and function in vivo , demonstrates that Gata1 plays an essential role in zebrafish hematopoiesis with significant conservation of function between mammals and zebrafish, and offers a powerful tool for future studies of the hematopoietic pathway.

21 August 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LCLea Cunningham
Lea Cunningham
SFSteven Finckbeiner
Steven Finckbeiner
RHR. Katherine Hyde
R. Katherine Hyde
NSNoel Southall
Noel Southall
JMJuan Marugan
Juan Marugan
PLPaul Liu
Paul Liu
Core binding factor (CBF) leukemias, those with translocations or inversions that affect transcription factor genes RUNX1 or CBFB , account for ∼24% of adult acute myeloid leukemia (AML) and 25% of pediatric acute lymphocytic leukemia (ALL). Current treatments for CBF leukemias are associated with significant morbidity and mortality, with a 5-y survival rate of ∼50%. We hypothesize that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. We developed high-throughput AlphaScreen and time-resolved fluorescence resonance energy transfer (TR-FRET) methods to quantify the RUNX1–CBFβ interaction and screen a library collection of 243,398 compounds. Ro5-3335, a benzodiazepine identified from the screen, was able to interact with RUNX1 and CBFβ directly, repress RUNX1/CBFB -dependent transactivation in reporter assays, and repress runx1 -dependent hematopoiesis in zebrafish embryos. Ro5-3335 preferentially killed human CBF leukemia cell lines, rescued preleukemic phenotype in a RUNX1–ETO transgenic zebrafish, and reduced leukemia burden in a mouse CBFB–MYH11 leukemia model. Our data thus confirmed that RUNX1–CBFβ interaction can be targeted for leukemia treatment and we have identified a promising lead compound for this purpose.

15 February 2009 in Development
Verified
Journal Article
Closed access
PDF file
HJHao Jin
Hao Jin
RSRaman Sood
Raman Sood
JXJin Xu
Jin Xu
FZFenghua Zhen
Fenghua Zhen
MEMilton A. English
Milton A. English
ZWZilong Wen
Zilong Wen
One unique feature of vertebrate definitive hematopoiesis is the ontogenic switching of hematopoietic stem cells from one anatomical compartment or niche to another. In mice, hematopoietic stem cells are believed to originate in the aorta-gonad-mesonephros (AGM), subsequently migrate to the fetal liver (FL) and finally colonize the bone marrow (BM). Yet, the differentiation potential of hematopoietic stem cells within early niches such as the AGM and FL remains incompletely defined. Here, we present in vivo analysis to delineate the differentiation potential of definitive hematopoietic stem/progenitor cells (HSPCs) in the zebrafish AGM and FL analogies, namely the ventral wall of dorsal aorta (VDA) and the posterior blood island (PBI), respectively. Cell fate mapping and analysis of zebrafish runx1w84x and vlad tepes (vltm651) mutants revealed that HSPCs in the PBI gave rise to both erythroid and myeloid lineages. However, we surprisingly found that HSPCs in the VDA were not quiescent but were uniquely adapted to generate myeloid but not erythroid lineage cells. We further showed that such distinct differentiation output of HSPCs was, at least in part, ascribed to the different micro-environments present in these two niches. Our results highlight the importance of niche in shaping the differentiation output of developing HSPCs.

24 March 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LCL. H. Castilla
L. H. Castilla
PPP. Perrat
P. Perrat
NMN. J. Martinez
N. J. Martinez
SLS. F. Landrette
S. F. Landrette
RKR. Keys
R. Keys
PLP. P. Liu
P. P. Liu
Acute myeloid leukemia subtype M4 with eosinophilia is associated with a chromosome 16 inversion that creates a fusion gene CBFB-MYH11 . We have previously shown that CBFB-MYH11 is necessary but not sufficient for leukemogenesis. Here, we report the identification of genes that specifically cooperate with CBFB-MYH11 in leukemogenesis. Neonatal injection of Cbfb-MYH11 knock-in chimeric mice with retrovirus 4070A led to the development of acute myeloid leukemia in 2-5 months. Each leukemia sample contained one or a few viral insertions, suggesting that alteration of one gene could be sufficient to synergize with Cbfb-MYH11 . The chromosomal position of 67 independent retroviral insertion sites (RISs) was determined, and 90% of the RISs mapped within 10 kb of a flanking gene. In total, 54 candidate genes were identified; six of them were common insertion sites (CISs). CIS genes included members of a zinc finger transcription factors family, Plag1 and Plagl2 , with eight and two independent insertions, respectively. CIS genes also included Runx2, Myb, H2T24 , and D6Mm5e . Comparison of the remaining 48 genes with single insertion sites with known leukemia-associated RISs indicated that 18 coincide with known RISs. To our knowledge, this retroviral genetic screen is the first to identify genes that cooperate with a fusion gene important for human myeloid leukemia.